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Overview
• Review historical perspective and complexity of primary CVD
prevention
• Discuss primary & secondary prevention of CAD and the 2019
ACC/AHA guidelines
• Review of the evidence & primary literature
• Focus on CV risk assessment, DM, ASA/DAPT
• Practical guidance and management considerations

• CASES- let’s practice and discuss

What we will not be talking about:
• Diagnosis and Management of acute coronary syndromes or ischemic
heart disease
• Cardiac imaging modalities for CAD stress tests, other imaging
modalities
• Cardiac catheterization, CABG and Revascularization procedures

CAD Prevention and Historical Context
Previous studies suggested as much has 50% patients with CHD had no
identifiable risk factors
Greenland et al(2003): 3 prospective cohort studies:
• Chicago Heart Association Detection Project (35 642 M/W 18-59)
• Multiple Risk Factor Intervention Trial (347 978 M 35-57)
• Framingham Heart Study (3295 M/W 34-59)
Main Outcomes: Fatal CHD nonfatal MI preceded by major CHD risk
factors (TC >240, SBP> 140, DBP >90 mm Hg cigarette smoking, and
diabetes)
Findings: For fatal CHD (n = 20 995) 87-100% had 1+ RF (87-94% 40-59y)
Non fatal MI 92% men, 87% of women

2010 AHA Model for Ideal CV Health

2019 ACC/AHA Guidelines on the Primary Prevention of
Cardiovascular disease

Top 10 Take-Home Messages

•2019 Primary
Prevention
Guidelines

Top 10 Take Home Messages
1. The most important way to prevent
atherosclerotic vascular disease, heart
failure, and atrial fibrillation is to promote a
healthy lifestyle throughout life.
How?

Top 10 Take home messages
2. A team-based care approach is an effective
strategy for the prevention of cardiovascular
disease. Clinicians should evaluate the
social determinants of health that affect
individuals to inform treatment decisions.
This includes emphasis on shared decision-making w/ patient and family

CMS
Screening
Tool

Top 10 Take Home Messages
3. Adults who are 40 to 75 years of age and are being
evaluated for cardiovascular disease prevention should
undergo 10-year atherosclerotic cardiovascular disease
(ASCVD) risk estimation and have a clinician–patient risk
discussion before starting on pharmacological therapy,
such as antihypertensive therapy, a statin, or aspirin. In
addition, assessing for other risk-enhancing factors can
help guide decisions about preventive interventions in
select individuals, as can coronary artery calcium
scanning.

Assessment of Cardiovascular Risk
Recommendations for Assessment of Cardiovascular Risk
COR

LOE
1.

I

IIa

IIa

B-NR
2.

For adults 20 to 39 years of age, it is reasonable to assess traditional
ASCVD risk factors at least every 4 to 6 years.

3.

In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or
intermediate risk (≥7.5% to <20% 10-year ASCVD risk), it is reasonable to
use additional risk-enhancing factors to guide decisions about preventive
interventions (e.g., statin therapy).

B-NR

B-NR

Recommendations
For adults 40 to 75 years of age, clinicians should routinely assess
traditional cardiovascular risk factors and calculate 10-year risk of ASCVD
by using the pooled cohort equations (PCE).

Assessment of Cardiovascular Risk (cont’d)
Recommendations for Assessment of Cardiovascular Risk
COR

LOE
4.

IIa

B-NR

5.
IIb

B-NR

Recommendations
In adults at intermediate risk (≥7.5% to <20% 10-year ASCVD risk) or
selected adults at borderline risk (5% to <7.5% 10-year ASCVD risk), if riskbased decisions for preventive interventions (e.g., statin therapy) remain
uncertain, it is reasonable to measure a coronary artery calcium score to
guide clinician–patient risk discussion.

For adults 20 to 39 years of age and for those 40 to 59 years of age who
have <7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk
may be considered.

Risk Calculator 40-75yrs old

CV Risk assessment in younger Adults:

Largely based on Framingham data and 30 year/lifetime risk estimates

Risk-Enhancing Factors
•

Family history of premature ASCVD (males, age <55 y; females, age <65 y)

•

Primary hypercholesterolemia (LDL-C 160–189 mg/dL [4.1–4.8 mmol/L]; non–HDL-C 190–219 mg/dL
[4.9–5.6 mmol/L])*

•

Metabolic syndrome (increased waist circumference [by ethnically appropriate cutpoints], elevated
triglycerides [>150 mg/dL, nonfasting], elevated blood pressure, elevated glucose, and low HDL-C [<40
mg/dL in men; <50 mg/dL in women] are factors; a tally of 3 makes the diagnosis)

•

Chronic kidney disease (eGFR 15–59 mL/min/1.73 m2 with or without albuminuria; not treated with
dialysis or kidney transplantation)

•

Chronic inflammatory conditions, such as psoriasis, RA, lupus, or HIV/AIDS

Risk-Enhancing Factors
•

History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that
increase later ASCVD risk, such as preeclampsia

•

High-risk race/ethnicity (e.g., South Asian ancestry)

•

Lipids/biomarkers: associated with increased ASCVD risk

•

Persistently elevated,* primary hypertriglyceridemia (≥175 mg/dL, nonfasting);

•

If measured:
§ Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)
§ Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An
Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of
Lp(a).
§ Elevated apoB (≥130 mg/dL): A relative indication for its measurement would be triglyceride ≥200
mg/dL. A level ≥130 mg/dL corresponds to an LDL-C >160 mg/dL and constitutes a risk-enhancing
factor
§ ABI (<0.9)

High- Sensitivity CRP and CAD
• Elevated CRP has been associated
with increased risk for CVD
• Independent of additional RFs
• Benefit in addition to traditional
CV risk estimates appears small
• Reclassifies risk in about 1.5%
• 1 CV event/10 yrs per 400-500
screened

• Benefit appears highest in those
with intermediate (10-20% 10yr
risk)

Who should I screen?:
Consider for those at intermediate
risk for whom it may impact
treatment decisions
What levels are abnormal?
<1mg/L = low risk
>2-3mg/L = higher risk

Lipoprotein a (Lp(a)) and CAD

Lp(a) and CAD
• Statin (+/- ezetimibe) therapy
not effective in lowering Lp(a)and may increase
• PCSK9 Ab’s have been
associated w/ 25% reduction in
Lp(a) and reductions mortality
and risk for MI
• Limited by costs- consider
stratifying use to those with high
Lp(a) and LDL above goal

Lp(a) and CAD- Who to Test?
• No clear consensus but elevated Lp(a) clearly associated w/
CAD risk
• Consider in non-diabetics 40-75yr at intermediate risk (to start
statin)
• Those with primary LDL>190—inc’d risk of Lp(a) excess or
premature ASCVD
• Those who cannot reach LDL goals with appropriate intensity
statin (+/- ezetimibe) to consider PCSK9Ab

Apolipoprotein B (ApoB) and CAD
• Apo B is the major apolipoprotein
in LDL+VLDL.
• Non-HDL is used as a surrogate
• Some studies have suggested
ApoB is a more potent marker of
CVD risk than LDL or non-HDL
• Others have shown non-HDL and
ApoB levels are highly corelated
• Less so with HyperTG

• When to consider ApoB:
• To assess risk for ASCVD for
patients with persistent
hypertriglyceridemia (>200
mg/dL)despite statin +/- fibrate
therapy

ABI and PAD screening in Cardiovascular Disease
• A 2005 meta-analysis of 9 studies found ABI <0.9 is specific
(92%) but not sensitive (16%) for predicting incident
cardiovascular disease (LR 2.53%), CV death (LR 5.6)
• Better for ruling in than ruling out CVD
• Presence of PAD is ASCVD equivalent and would warrant
treatment as such

Coronary Artery Calcium Scoring
Adding CAC to traditional CV risk
calculators yielded risk estimates 8-9%
higher for those participants who had CV
events vs non-events
Calculator

Table 6. Selected Examples of Candidates for CAC Measurement
Who Might Benefit from Knowing Their CAC Score is Zero
CAC Measurement Candidates Who Might Benefit from Knowing Their CAC
Score Is Zero
•
•
•

•

Patients reluctant to initiate statin who wish to understand their risk and
potential for benefit more precisely
Patients concerned about need to reinstitute statin therapy after
discontinuation for statin-associated symptoms
Older patients (men 55–80 y of age; women 60–80 y of age) with low
burden of risk factors (S4.4-42) who question whether they would benefit
from statin therapy
Middle-aged adults (40–55 y of age) with PCE-calculated 10-year risk for
ASCVD 5% to <7.5% with factors that increase their ASCVD risk, although
they are in a borderline risk group.

CAC and CV risk: Take home Points
• Consider in adults at intermediate
risk (≥7.5-<20% 10-year ASCVD) or
selected adults at borderline risk (5<7.5% 10-year ASCVD)
• CAC < 1 is highly predictive of low 10
yr. CV risk (most useful in ruling out
significant CAD risk)
• CAC >100 is predictive of at least
intermediate risk

• Limitations:
• Not covered my most insurance
companies ($100-400)
• Radiation risk

Take home points:
• For patients at intermediate ASCVD risk consider:
• Advanced biomarker testing --Hs-CRP, Lp(a) (best data), apoB
• ABI
• Coronary Artery calcium scoring
… After assessing for risk enhancing conditions IF it will change
management/risk classification

Top 10 Take Home Messages
4. All adults should consume a healthy diet that
emphasizes the intake of vegetables, fruits, nuts,
whole grains, lean vegetable or animal protein, and
fish and minimizes the intake of trans fats, red meat
and processed red meats, refined carbohydrates, and
sweetened beverages. For adults with overweight and
obesity, counseling and caloric restriction are
recommended for achieving and maintaining weight
loss.

Top 10 Take Home Messages
5. Adults should engage in at least 150 minutes
per week of accumulated moderateintensity physical activity or 75 minutes per
week of vigorous-intensity physical activity.

Americans and Exercise:
Intensity
Sedentary
behavior*
Light

METs
1–1.5

Moderate

3.0 –5.9

Vigorous

≥6

1.6–2.9

Examples
Sitting, reclining, or lying;
watching television
Walking slowly, cooking, light
housework
Brisk walking (2.4–4 mph),
biking (5–9 mph), ballroom
dancing,
active
yoga,
recreational swimming
Jogging/running, biking (≥10
mph),
singles
tennis,
swimming laps

Top 10 Take Home Messages
6. For adults with type 2 diabetes mellitus,
lifestyle changes, such as improving dietary
habits and achieving exercise
recommendations, are crucial. If medication
is indicated, metformin is first-line therapy,
followed by consideration of a sodiumglucose cotransporter 2 inhibitor or a
glucagon-like peptide-1 receptor agonist.

Fig. 2. Treatment of T2DM for Primary Prevention of CVD

Metformin and CVD Risk Reduction

Metformin and CVD Risk Reduction
• 2017 Meta-analysis of 13 RCTs
Metformin vs Placebo:
• All outcomes, with the exception
of stroke, favored metformin.
None significant
• Effect sizes:
• All-cause mortality 0.96 (95% CI
0.84, 1.09)
CV Death 0.97 (95% CI 0.80, 1.16)
MI 0.89 (95% CI 0.75, 1.06)
Stroke 1.04 (95% CI 0.73, 1.48)
PVD 0.81 (95% CI 0.50, 1.31)

SGLT-2 Inhibitors and CVD Risk Reduction

GLP-1 Agonists and CVD Risk Reduction
• Significant reductions to 3 point
MACE, CV mortality and all cause
• No overall inc. in Aes
• Limitations:
• Only patients w/ known CAD
included in trials
• No clear evidence of fatal and
non-fatal MI reduction

Comparison of DM drug classes in CV Disease Outcomes

Top 10 Take Home Messages
7. All adults should be assessed at every
healthcare visit for tobacco use, and those
who use tobacco should be assisted and
strongly advised to quit.

Top 10 Take Home Messages
8. Aspirin should be used infrequently in the
routine primary prevention of ASCVD because
of lack of net benefit.

Aspirin Use
Recommendations for Aspirin Use
COR

LOE
1.

IIb

III:
Harm
III:
Harm

A
2.

Low-dose aspirin (75-100 mg orally daily) should not be administered on
a routine basis for the primary prevention of ASCVD among adults >70
years of age.

3.

Low-dose aspirin (75-100 mg orally daily) should not be administered
for the primary prevention of ASCVD among adults of any age who are
at increased risk of bleeding.

B-R

C-LD

Recommendations
Low-dose aspirin (75-100 mg orally daily) might be considered for the
primary prevention of ASCVD among select adults 40 to 70 years of age
who are at higher ASCVD risk but not at increased bleeding risk.

ASA for Primary Prevention of CAD
• ASCEND: RCT of 15,480 patients
with DM, no known CAD (mean
f/u 7.4 years)
• Most pts on statin(75%), HTN Tx
• 12% lower risk for CV events
• 29% higher major bleeding risk

ASA for Primary Prevention of CAD
• Based on this data USPSTF made
grade B rec for adults 50-59 w/
>10% 10yr ASCVD risk (C for 6069 and I for <50 or >70yo)
• ASA has failed to show robust
benefit across multiple study
groups for primary prevention
(low ABI, DM)

22% dec in non-fatal MI, 6% all cause

ASA for Primary Prevention of CAD
• Despite reducing evidence of
benefits NNT to prevent ASCVD
event > NNH via bleeding event
• Consider ASA If: No factors
increasing bleeding risk, ASCVD
risk >10% and/or patient is
unable to control other ASCVD
risk factors- shared decision
making with patient

How Do we Assess Bleeding Risk?
•
•
•
•
•
•
•

Hx of previous GI bleed/PUD
Hx of ICH/other significant bleed
age >70 years,
Thrombocytopenia
coagulopathy
CKD
Concurrent use of:
• NSAIDS, Steroids, DOACs/warfarin,
SSRI

• http://www.asariskcalculator.com/

• http://www.aspiringuide.com

Top 10 Take Home Messages
9. Statin therapy is first-line treatment for
primary prevention of ASCVD in patients
with elevated low-density lipoprotein
cholesterol levels (≥190 mg/dL), those with
diabetes mellitus, who are 40 to 75 years of
age, and those determined to be at
sufficient ASCVD risk after a clinician–
patient risk discussion.

Top 10 Take Home Messages
10.Nonpharmacological interventions are
recommended for all adults with elevated
blood pressure or hypertension. For those
requiring pharmacological therapy, the
target blood pressure should generally be
<130/80 mm Hg.

Figure 4. BP Thresholds and Recommendations for Treatment

BP indicates blood pressure; and CVD, cardiovascular disease.

Table 7. Best Proven Nonpharmacological Interventions For
the Prevention and Treatment of Hypertension
Nonpharmacological
Intervention

Weight loss

Weight/body fat

Healthy diet

DASH dietary pattern‡

Reduced intake Dietary sodium
of dietary sodium

Enhanced intake Dietary potassium
of dietary
potassium

Goal
Best goal is ideal body
weight, but aim for at least
a 1-kg reduction in body
weight for most adults who
are overweight. Expect
about 1 mm Hg for every 1kg reduction in body
weight.
Consume a diet rich in
fruits, vegetables, whole
grains, and low-fat dairy
products, with reduced
content of saturated and
total fat.
Optimal goal is <1500
mg/d, but aim for at least a
1000-mg/d reduction in
most adults.
Aim for 3500–5000 mg/d,
preferably by consumption
of a diet rich in potassium.

Approximate Impact on SBP
Hypertension Normotension
Reference
-5 mm Hg

-2/3 mm Hg

(S4.4-2)

-11 mm Hg

-3 mm Hg

(S4.4-7, S4.4-8)

-5/6 mm Hg

-2/3 mm Hg

(S4.4-12, S4.4-10)

-4/5 mm Hg

-2 mm Hg

(S4.4-14)

Table 7. Best Proven Nonpharmacological Interventions For
the Prevention and Treatment of Hypertension (cont’d)
Nonpharmacological
Intervention
Physical activity

Goal

Aerobic

•
•

Dynamic resistance

•
•
•

Isometric resistance

Moderation in
alcohol intake

Alcohol consumption

•

Approximate Impact on SBP
Hypertension Normotension
Reference

90–150 min/wk
-5/8 mm Hg
65%–75% heart rate
reserve
90–150 min/wk
-4 mm Hg
50%–80% 1 rep
maximum
6 exercises, 3
sets/exercise, 10
repetitions/set

4 × 2 min (hand
-5 mm Hg
grip), 1 min rest
between exercises,
30%–40% maximum
voluntary
contraction, 3
sessions/wk
•
8–10 wk
In individuals who drink
-4 mm Hg
alcohol, reduce alcohol† to:
•
Men: ≤2 drinks daily
•
Women: ≤1 drink
daily

-2/4 mm Hg

(S4.4-19, S4.4-20)

-2 mm Hg

(S4.4-19)

-4 mm Hg

(S4.4-21, S4.4-63)

-3 mm Hg

(S4.4-20, S4.4-24,
S4.4-25)

What’s the data for intensive BP control?

Take home points re: Treatment goals
• BP target <130/80 w/ pharmacotherapy if:
• 10 year ASCVD risk >10%
• CKD
• DM2

• Data suggests this may contribute to reduction in major CV
events and MI but overall mortality benefit unclear

2019 ACC/AHA Guidelines on the Primary Prevention of
Cardiovascular disease

Clinic Evaluation of Patients with Stable CAD (SIHD)
• At least Annual Follow up:
• a. Assessment of symptoms and clinical function;
• b. Surveillance for complications: heart failure and arrhythmias
• c. Monitor risk factors: re-assess lifestyle & medical therapy

• IF evidence of MI or worsening HF: asses LVEF and segmental
wall motion by echocardiography or radionuclide imaging
• Consider resting 12-lead ECG at 1-year or longer if symptoms
stable
• No evidence for routine echo in stable patients with normal EF

Secondary Prevention : Guidelines Directed Medical
Therapy
• Lifestyle modifications
• Physical activity, weight mgmt, dietary mod, tobacco cessation,
ETOH moderation

• Lipid management as per 2018 AHA/ACC guidelines (high-or
moderate-intensity statin)
• HTN management: Goal BP <130/80 (especially if DM or CKD)
• include ACEi (or ARB) and/or beta blockers. Other meds as need to
achieve BP goal.

• Optimize diabetic control A1c<7% (metformin+ GLP1 or SGLT2i)
• Antiplatelet therapy- ASA 81mg (A,Clopidogrel (B) if contraind.)

Secondary Prevention : Guideline Directed Medical
Therapy (Goal: prevent second event)
• HTN management: Goal BP <130/80 (especially if DM or CKD)
•
•
•
•

BP targets somewhat controversial
ACEi/ARB (Hx of MI, CHF/LV dysf/CKD, DM)
Beta blocker: Hx of MI, angina, LV dysfunction
Adjuncts:
• Aldosterone antagonist if LV dysf (<40%EF)
• Calcium channel blocker if angina

• Optimize diabetic control A1c<7% (B) (SDM older patients)
• metformin+ GLP1 or SGLT2i (Avoid Thiazolidinediones)

Comparison of DM drug classes in CV Disease Outcomes

Use of Beta Blockers to Prevent MI, CV death:
• Beta-blocker:
• 3 years in all patients with normal LV function after MI or
ACS(IB)
• all patients with LV systolic dysfunction (EF ≤40%) with heart
failure or prior MI
• carvedilol, metoprolol succinate, or bisoprolol: demonstrated
mortality benefit (IA)

• Consider for all other patients with CAD

DAPT: Dual Antiplatelet Therapy
• No indication unless recent MI,
PCI, CABG
• All patients with CAD s/p ACS
• 12 mo DAPT (regardless of
intervention)

• SIHD requiring intervention:
• BMS: >1mo
• DES >6 mo
• CABG: 12 mo (less clear data)

• Consider longer duration if
thrombotic risk>bleeding risk

Duration of DAPT: Ischemia vs Bleeding Risk

*Consider PPI for those at inc. bleeding
risk (I-Hx GIB, IIa-other inc risk)

Cardiac Rehabilitation
• Meta-analysis of 48 RCTs of exercise
interventions (med duration 3mo):
• 20% reduction in all-cause mortality
• 26% reduction in CV mortality
• Non-sig but fav. Trends:
•

• When to Refer:
•
•

nonfatal MI, CABG, PCI

• No difference between the mortality
rate effects of exercise-only and
more comprehensive cardiac
rehabilitation interventions, and the
benefits were independent of actual
amount and intensity of exercise.

•

Recent ACS s/p CABG or PCI @ hospital
d/c or TOC(IA)
Dx in last 1 yr:
• ACS s/p CABG or PCI (IA)
• chronic angina (IB)
• PAD (IA)
• Clinically stable outpatients with
diagnosis of heart failure (IIa/B)
Can substitute home based cardiac
rehab program for low risk patients (IA)

Pharmacotherapy for Chronic Anginal Sx:
• 1st line: Beta blockers (IB)
• 2nd line: Calcium channel blockers or long-acting nitrates (IB)
–if unable to tolerate BB
• Add: Calcium channel blockers or long-acting nitrates if
persistent sx on BB
• Sublingual nitroglycerin or nitroglycerin spray is
recommended for immediate relief

Checklist for your patients with CAD:
ü ASA therapy?
ü Indication for DAPT?
ü ACS/PCI/CABG in last 12 mo

ü Beta blocker?
ü ACEi/ARB?
ü High intensity statin?
ü Diabetic control?

ü ETOH moderation/cessation
ü Depression/socioeconomic
screening
ü Physical activity/weight mgmt
ü Eval chronic angina?
ü BB, CCB or nitrate

ü If A1c >7 consider GLP1, SGLT-2

ü Tobacco cessation?

ü Assess for interval MI, sx of
worsening HF

Coronary Artery Disease: CASES
in Primary Prevention

Case 1
• 55yo Male with PMH HTN, DM,
remote PUD, tobacco use
presents for a NPV TOC visit after
recent stay in OSH with a recent
STEMI of LAD managed with PCI
and DES stent. Echocardiogram
prior to discharge showed EF of
35%.
• Labs: A1c 8.8%, LDL 186, TG 255,
HDL 30, Cr 1.2
VS: HR 82, BP 150/92, BMI 43

• His current meds are:
ASA 81mg, Clopidogrel 75mg daily,
Metformin 1000mg BID, Lisinopril
40mg, Atorvastatin 40mg,
Furosemide 20mg daily
1. How would you counsel this
patient?
2. What management recs would you
make?

Case 2
• 52yo AAF Female presents to your
office to establish care. Her PMH is
significant for HTN, Depression and
HIV. Her BP is 130/76. BMI 32
• Her meds are as follows:
Chlorthalidone 25mg,
Darunavir/ritonavir + Descovy
(TAF/Emtricitabine), Sertraline
100mg

•
•
•
•
•
•
•

Labs:
Tot Chol: 205
HDL 35
LDL 126
A1c: 6.0%
Cr 1.4 (CrCl 49)
VL <40, CD4 450

• She is a non-smoker
• She is reluctant to change any meds

• Assess her ASCVD 10yr risk
• Discuss any medication changes or
additional testing.

Case 3
• 56yoM w/ PMH severe Hip OA DM2, CAD s/p NSTEMI w/ PCI
and DES 3 months ago comes to you for pre-operative
evaluation an clearance. He has completed cardiac rehab
program and is symptom free on the following meds:
• ASA 81mg, Atorvastatin 40mg, metoprolol XL 50mg daily, Lisinopril 20mg daily,
clopidogrel 75mg daily, metformin 1000mg BID, lantus 20 units daily

1. Any other information to you want to know?
2.Would you make any changes to his medication regimen?
3. How would you counsel him regarding his procedure?

Perioperative management & DAPT in CAD

Case 4
• 47yo Caucasian Male presents to your office to review his
biometric screening results:
• TC: 250, HDL 30, LDL 170, TG 250, A1c 5.8%, BP 138/86

• He is a non-smoker, his BMI is 36, and he has been taking ASA
81 mg for the last 6 mo after his brother died at 54 from MI
• He wants to do EVERYTHING to reduce his CV risk. How
would you counsel him? Additional testing? Meds?

Case 5
• 75yo AA Female who present for routine follow up. She has a
remote hx of MI treated with PCA in her 50s, HTN, DM, CKD,
GERD. She is a former smoker and quit 15 yrs ago. Echo last
year showed EF 45%. Her BP is 140/86 on exam.
• Labs: A1c: 8%, LDL 66, HDL 40, Tot Chol: 180, Cr 1.4 (CrCl 40)
• Meds: ASA 81mg, Atorvastatin 80mg, Metformin 100mg BID,
Metoprolol 50mg, lisinopril 20mg, Omeprazole 40mg
• Would you make any changes to he regimen? Considerations?
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